GSK Shingrix Shingles Vaccine Could Get CDC Panel Nod For Use In Immunocompromised Adults

Phase III trials found vaccine effectiveness was 68.2% in recipients with autologous hematopoietic stem cell transplant and 87.2% in those with hematologic malignancies, GSK tells Advisory Committee on Immunization Practices.

Shingrix
GlaxoSmithKline moves to expand Shingrix vaccine for use in immunocompromised adults • Source: Alamy

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is evaluating whether to recommend GlaxoSmithKline plc’s blockbuster shingles vaccine Shingrix for use in immunocompromised adults 19 years of age and older, which would expand its availability to millions of additional people.

At ACIP’s 25 June meeting, ACIP’s herpes zoster work group reported its initial discussions on use of Shingrix (zoster vaccine,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers